Alzheimer’s and neurological testing is moving into blood. Fujirebio just cleared two assays in Canada
Health Canada has issued Class II medical-device licenses for Fujirebio’s Lumipulse G pTau217 Plasma and NfL Blood assays, expanding automated blood-based neurological testing for Alzheimer’s pathology and neuro-axonal injury.
